



IAF3 Rec'd PCT/PTO 01 FEB 2006

PATENT
ATTORNEY DOCKET: 59866.000002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 09/546,573 Confirmation No.: 3408
Applicant : Mads HOLTEN-ANDERSEN, et al.
Filed : April 10, 2000
Title : TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES
TYPE-1(TIMP-1) AS A CANCER MARKER
TC/Art Unit : 1643
Examiner: : S. L. Rawlings

Docket No. : 59866.000002
Customer No. : 21967

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants submit attached Form PTO-SB/08A (modified) for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Applicant wishes to inform the Examiner of the existence of the following co-pending U.S. patent application:

U.S. Patent Application No. 10/470,658 filed March 28, 2005, entitled "A Method for Detecting, Screening, and /or Monitoring a Cancer in an Individual" (attorney docket number: 59866.000005). A copy of this U.S. Patent Application as filed is enclosed.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references is enclosed with this communication. In considering the cited

references, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.


In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action on the merits, or a Notice of Allowance. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: February 1, 2006

By:


Stanislaus Aksman
Registration No. 28,562

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)
SA/asc



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Application Number	09/546,573
Filing Date	April 10, 2000
First Named Inventor	Mads HOLTEN-ANDERSEN, et al
Art Unit	1643
Examiner Name	S. L. Rawlings
Attorney Docket Number	59866.000002


Sheet **2 of 3****OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	2.	Agency for Health Care Policy and Research, "Colorectal Cancer Screening: Summary", Evidence Report: Number 1. AHCPR Publ. No. 97-0302, pg. 1-4.	<input type="checkbox"/>	<input type="checkbox"/>
	3.	Aznavorian S. et al., "Molecular Aspects of Tumor Cell Invasion and Metastasis", Cancer, 15, 71(4), pg. 1368-1383, 1993.	<input type="checkbox"/>	<input type="checkbox"/>
	4.	Balk, S. P. et al., "Biology of Neoplasia, Biology of Prostate-Specific Antigen", Journal of Clinical Oncology, 21 (2), pg. 383-391, 2003.	<input type="checkbox"/>	<input type="checkbox"/>
	5.	Benson, A. B., et al., "ASCO Special Article - 2000 Update of American Society Colorectal Cancer Surveillance Guidelines", Journal of Clinical Oncology, 18(20), pg. 3586-3588, October 15, 2000.	<input type="checkbox"/>	<input type="checkbox"/>
	6.	Birkedal-Hansen, "Role of Matrix Metalloproteinases in Human Periodontal Diseases", J. Periodontal., pg. 474-484, May 1993.	<input type="checkbox"/>	<input type="checkbox"/>
	7.	Breimer, D. D., et al., "Saliva: A Fluid for Measuring Drug Concentrations", Pharmacy Internation, 1, pg. 9-11, 1980.	<input type="checkbox"/>	<input type="checkbox"/>
	8.	Khokha, R. et al., "AntisenseRNA-Induced Reduction in Murine TIMP Levels Confers Oncogenicity on Swiss 3T3 Cells", Science, 243, pg. 947-950, February 17, 1989.	<input type="checkbox"/>	<input type="checkbox"/>
	9.	Kleiner, et al., "Stability Analysis of Latent and Active 72-kDa Type IV Collagenase: The Role of Tissue Inhibitor of Metalloproteinases-2 (TIMP-2)", Biochemistry, 32, pg. 1583-1592, 1993.	<input type="checkbox"/>	<input type="checkbox"/>
	10.	Lovgren, J., et al., "Measurement of Prostate-Specific Antigen and Human Glandular Kallikrein 2 in Different Body Fluids", J. Andrology, 20, pg. 348-355, 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	11.	Remacle, A. et al., "High Levels of TIMP-2 Correlate with Adverse Prognosis in Breast Cancer", Int. J. Cancer, 89, pp: 118-121, 2000.	<input type="checkbox"/>	<input type="checkbox"/>
	12.	Stetler-Stevenson WG et al., "Matrix Metalloproteinases and Tumor Invasion: From Correlation and Causality to the Clinic", Semin. Cancer. Biol., 7, pp. 147-154, 1996.	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/546,573
		Filing Date	April 10, 2000
		First Named Inventor	Mads HOLTEN-ANDERSEN, et al.
		Art Unit	1643
		Examiner Name	S. L. Rawlings
Sheet	3 of 3	Attorney Docket Number	59866.000002

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	13.	Turan T. et al., "Free and Total Prostate-Specific Antigen Levels in Saliva and the Comparison with Serum Levels in Men", Eur. Urol., 38(5), pp. 550-554, 2000.	<input type="checkbox"/>	<input type="checkbox"/>
	14.	Vignola et al., "Sputum Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio Correlates with Airflow Obstruction in Asthma and Chronic Bronchitis", Am. J. Respir. Crit. Care Med., 158, pp. 1945-1950, 1998.	<input type="checkbox"/>	<input type="checkbox"/>
	15.	Vining, R. and McGinley, RA, "Hormones in Saliva", Critical Reviews in Clinical Laboratory Science, 23, pp. 95-146, 1985.	<input type="checkbox"/>	<input type="checkbox"/>
	16.	Welgus HG et al., "Human Skin Fibroblast Collagenase Interaction with Substrate and Inhibitor", Coll. Relat. Res., 5, pp. 167-179, 1985.	<input type="checkbox"/>	<input type="checkbox"/>
	17.	Wolff, K. et al., Hay, A., "Methadone in Saliva", Clinical Chemistry, 37, pp. 1297-1298, 1991.	<input type="checkbox"/>	<input type="checkbox"/>
	18.	Garrett, C. Durkan et al., "Prognostic Significance of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-1 in Voided Urine Samples from Patients with Transitional Cell Carcinoma of the Bladder", Clin. Cancer Res., 7, pp. 3450-3456, Nov. 2001.	<input type="checkbox"/>	<input type="checkbox"/>
	19.	Birkedal-Hansen, H. et al., "Matrix Metalloproteinases: A Review", Crit. Rev. Oral. Biol. Med., 4(2), pp 197-250, 1993.	<input type="checkbox"/>	<input type="checkbox"/>
	20.	McCarthy K. et al., "High Levels of Tissue Inhibitor of Metalloproteinase-1 Predict Poor Outcome in Patients with Breast Cancer", Int. J. Cancer, 84, pp. 44-48, 1999.	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE	DATE CONSIDERED
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.